Cargando…
Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature
Fragile X syndrome (FXS) is an X-linked dominant disorder caused by a mutation in the fragile X mental retardation 1 gene. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for individuals with anxiety, poor sleep, and cognitive deficits, as well as populations with endoc...
Autores principales: | Tartaglia, Nicole, Bonn-Miller, Marcel, Hagerman, Randi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446166/ https://www.ncbi.nlm.nih.gov/pubmed/30944868 http://dx.doi.org/10.1089/can.2018.0053 |
Ejemplares similares
-
Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment
por: Palumbo, Joseph M., et al.
Publicado: (2023) -
Fragile X Syndrome
por: McLennan, Yingratana, et al.
Publicado: (2011) -
A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2022) -
Fragile X syndrome and fragile X-associated disorders
por: Rajaratnam, Akash, et al.
Publicado: (2017) -
Aging in fragile X syndrome
por: Utari, Agustini, et al.
Publicado: (2010)